首頁 > 市場調查報告書 > 醫療設備

藥物遞輸設備

市場調查報告書

商品編碼

1534243

全球口腔給藥系統市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢與預測

Global Buccal Drug Delivery System Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年07月01日 | 出版商:

Value Market Research | 英文 171 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球口腔給藥系統市場需求預計將從 2023 年的 47 億美元達到 2032 年近 84.1 億美元的市場規模，2024-2032 年研究期間複合年成長率為 6.68%。

口腔給藥系統是指透過臉頰或口底的黏膜內層給藥。此途徑可讓藥物繞過胃腸道和肝臟代謝，有可能提高生物利用度和治療效果。口腔給藥系統有多種形式，包括貼片、片劑和薄膜，旨在黏附在口腔黏膜上並釋放藥物以直接吸收到血液中。

市場動態

在多種因素的推動下，口腔給藥系統市場可望顯著成長。首先，患者對非侵入性給藥方法的偏好，加上給藥的便利性和患者依從性的提高，促進了口腔給藥系統的採用。製藥公司越來越投入研發資金來開發可增強藥物吸收和作用持續時間的新型配方。此外，透過口腔途徑輸送小分子和生物製劑的潛力擴大了各個治療領域的應用範圍，包括疼痛管理、荷爾蒙治療和神經系統疾病。此外，黏膜黏附聚合物和滲透增強劑等配方技術的進步克服了藥物吸收的障礙並改善了治療效果，有助於市場的擴張。監管機構擴大接受口腔給藥系統作為傳統途徑的有效且安全的替代品，這進一步促進了市場的成長。

此外，全球人口老化和慢性病的盛行率上升推動了對創新藥物輸送解決方案的需求，這些解決方案可提高療效並減少副作用。此外，製藥公司和研究機構之間的合作促進了針對特定患者需求的客製化口腔配方的開發，透過產品差異化和擴大市場滲透率促進市場成長。然而，嚴格的監管要求和在患者群體中實現一致的藥物吸收率的挑戰可能會阻礙口腔給藥系統市場的成長。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對口腔給藥系統全球市場的各個細分市場進行了包容性評估。口腔給藥系統產業的成長和趨勢為本研究提供了整體方法。

市場區隔

口腔給藥系統市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略家確定相應產品或服務的目標人群以及即將到來的機會。

按類型

舌下膜和薄片
含片/含片
口腔噴霧劑

按申請

疼痛管理
戒菸
心絞痛
其他

按最終用途

醫院
門診中心
其他（診所、家庭健康/非處方藥）

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲口腔給藥系統市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。口腔給藥系統市場的主要參與者包括 GSK Plc、Teva Pharmaceutical Industries Ltd.、輝瑞 Inc.、Generex Biotechnology Corporation (Lumitos AG)、ARx LLC.、Endo Inc.、Catalent Inc.、Cynapsus Therapeutics Inc.、Collegium Pharmaceutical ，獨立PLC。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區按國家銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲按國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 9 章：口腔給藥系統公司的競爭格局

口腔給藥系統市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 10 章：公司簡介

頂級公司市佔率分析
市場集中度
GSK Plc

公司概況
公司收入
產品
最新動態

Teva Pharmaceutical Industries Ltd.

公司概況
公司收入
產品
最新動態

Pfizer Inc.

公司概況
公司收入
產品
最新動態

Generex Biotechnology Corporation (Lumitos AG)

公司概況
公司收入
產品
最新動態

ARx LLC.

公司概況
公司收入
產品
最新動態

Endo Inc.

公司概況
公司收入
產品
最新動態

Catalent Inc

公司概況
公司收入
產品
最新動態

Cynapsus Therapeutics Inc.

公司概況
公司收入
產品
最新動態

Collegium Pharmaceutical

公司概況
公司收入
產品
最新動態

Indivior PLC

公司概況
公司收入
產品
最新動態

註 - 在公司概況中，財務詳細資訊和最新發展視情況而定，或對私人公司而言可能不包括在內

簡介目錄圖表

Product Code: VMR112115326

The global demand for Buccal Drug Delivery System Market is presumed to reach the market size of nearly USD 8.41 Billion by 2032 from USD 4.7 Billion in 2023 with a CAGR of 6.68% under the study period 2024-2032.

The buccal drug delivery system refers to administering medications through the mucosal lining of the cheek or the floor of the mouth. This route allows drugs to bypass the gastrointestinal tract and liver metabolism, potentially improving bioavailability and therapeutic efficacy. Buccal delivery systems come in various forms, including patches, tablets, and films, designed to adhere to the buccal mucosa and release medications for absorption directly into the bloodstream.

MARKET DYNAMICS

The buccal drug delivery system market is poised for significant growth driven by several factors. Firstly, patient preference for non-invasive drug delivery methods, coupled with the ease of administration and improved patient compliance, boosts the adoption of buccal delivery systems. Pharmaceutical companies are increasingly spending R&D to develop novel formulations that enhance drug absorption and duration of action. Moreover, the potential for delivering small molecules and biologics through the buccal route expands the application scope across various therapeutic areas, including pain management, hormonal therapies, and neurological disorders. Furthermore, advancements in formulation technologies such as mucoadhesive polymers and permeation enhancers contribute to the market's expansion by overcoming barriers to drug absorption and improving therapeutic outcomes. Regulatory agencies' growing acceptance of buccal drug delivery systems as effective and safe alternatives to traditional routes further catalyzes market growth.

Moreover, the aging population and the rising prevalence of chronic diseases worldwide drive the demand for innovative drug delivery solutions that offer enhanced efficacy and reduced side effects. Additionally, partnerships between pharmaceutical companies and research institutions facilitate the development of customized buccal formulations tailored to specific patient needs, fostering market growth through product differentiation and expanded market penetration. However, stringent regulatory requirements and challenges in achieving consistent drug absorption rates across patient populations can hamper buccal drug delivery system market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Buccal Drug Delivery System. The growth and trends of Buccal Drug Delivery System industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Buccal Drug Delivery System market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

Sublingual Films and Wafers
Buccal Tablets/Lozenges
Oral Sprays

By Application

Pain Management
Smoking Cessation
Angina Pectoris
Others

By End-use

Hospitals
Ambulatory Centers
Others (Clinics, Home Health/OTC)

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Buccal Drug Delivery System market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Buccal Drug Delivery System market include GSK Plc, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Generex Biotechnology Corporation (Lumitos AG), ARx LLC., Endo Inc., Catalent Inc, Cynapsus Therapeutics Inc., Collegium Pharmaceutical, Indivior PLC. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. BUCCAL DRUG DELIVERY SYSTEM - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type
- 3.7.2 Market Attractiveness Analysis By Application
- 3.7.3 Market Attractiveness Analysis By End-use
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL BUCCAL DRUG DELIVERY SYSTEM MARKET ANALYSIS BY TYPE

5.1. Overview By Type
5.2. Historical and Forecast Data Analysis By Type
5.3. Sublingual Films and Wafers Historic and Forecast Sales By Regions
5.4. Buccal Tablets/Lozenges Historic and Forecast Sales By Regions
5.5. Oral Sprays Historic and Forecast Sales By Regions

6. GLOBAL BUCCAL DRUG DELIVERY SYSTEM MARKET ANALYSIS BY APPLICATION

6.1. Overview By Application
6.2. Historical and Forecast Data Analysis By Application
6.3. Pain Management Historic and Forecast Sales By Regions
6.4. Smoking Cessation Historic and Forecast Sales By Regions
6.5. Angina Pectoris Historic and Forecast Sales By Regions
6.6. Others Historic and Forecast Sales By Regions

7. GLOBAL BUCCAL DRUG DELIVERY SYSTEM MARKET ANALYSIS BY END-USE

7.1. Overview By End-use
7.2. Historical and Forecast Data Analysis By End-use
7.3. Hospitals Historic and Forecast Sales By Regions
7.4. Ambulatory Centers Historic and Forecast Sales By Regions
7.5. Others (Clinics, Home Health/OTC) Historic and Forecast Sales By Regions

8. GLOBAL BUCCAL DRUG DELIVERY SYSTEM MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE BUCCAL DRUG DELIVERY SYSTEM COMPANIES

9.1. Buccal Drug Delivery System Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF BUCCAL DRUG DELIVERY SYSTEM INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. GSK Plc
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. Teva Pharmaceutical Industries Ltd.
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Pfizer Inc.
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. Generex Biotechnology Corporation (Lumitos AG)
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. ARx LLC.
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. Endo Inc.
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. Catalent Inc
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. Cynapsus Therapeutics Inc.
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. Collegium Pharmaceutical
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. Indivior PLC
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments